Login / Signup

Copper chelation in patients with hypertrophic cardiomyopathy.

Anna ReidChristopher MillerJohn Peter FarrantRahul PolturiDavid ClarkSimon RayGarth CooperMatthias Schmitt
Published in: Open heart (2022)
-selective chelation with trientine in a controlled environment is safe and a potential future therapeutic target. A phase 2b trial is now underway.
Keyphrases
  • hypertrophic cardiomyopathy
  • left ventricular
  • study protocol
  • phase iii
  • current status
  • clinical trial
  • phase ii
  • human health
  • randomized controlled trial
  • oxide nanoparticles
  • risk assessment